Ventures
Invest in breakthrough healthtech solutions that transform patients' lives.

Receive the latest investment opportunities that match your interests, directly in your inbox. Stay informed and never miss out.
a highlight from our portfolio

Angiogenesis Analytics

PEP Health
Persuasive addresses the challenge of identifying Stable Angina patients early on, crucial for preventing heart attacks. Currently, without a diagnostic test in general practitioner settings, many referrals to hospitals prove unnecessary. The solution is a simple blood test, leveraging an extracellular vesicle protein signature to distinguish SA patients from those with non-cardiac chest pain. This innovative approach promises to streamline patient management, saving lives and healthcare resources.

NLC's venture, Profionics, advances Cardiff University's sepsis research with a biomarker test combining AI, gene expression, and metabolic analysis for rapid, accurate diagnosis. This test, which works in under 30 minutes with a drop of blood, surpasses traditional methods by quickly identifying those needing antibiotics and reducing unnecessary use, thus combating antimicrobial resistance and saving lives. Particularly impactful in neonatal care, it ensures timely detection critical for newborn survival. Founded by NLC, Cardiff University, and CEO Darren Fergus, Profionics leverages extensive research and a blood sample BioBank, positioning itself as a leader in host response diagnostic testing.

Haermonics addresses the challenge of complications after open heart surgery with a transformative solution. Excessive blood loss and clots post-surgery lead to numerous issues, including reoperations and cardiac tamponades, resulting in significant healthcare costs and loss of lives. The Haermonics Flush device offers a preventive approach by flushing the pericardial cavity after surgery, limiting blood loss and clot formation. By providing medical professionals with better patient status monitoring, Haermonics Flush empowers doctors to make more informed decisions, ultimately saving thousands of lives and billions in hospital costs.

Allergios revolutionizes allergy diagnosis by directly visualizing the allergic response in patient blood, offering a more accurate alternative to current tests like skin prick and IgE blood tests. Additionally by analyzing how blood serum reacts to allergens. With its disposable chip, optical reader, and AI-based analysis software, Allergios helps millions of allergy sufferers worldwide access timely and effective treatment options.

ArtiFex tackles a solution for coronary and peripheral bypass surgeries. Traditional grafts from the great saphenous vein face issues like rapid degeneration, leading to complications. With millions of bypass surgeries conducted annually and a billion-dollar market for vascular grafts, there's a clear need for improvement. ArtiFex's innovative vascular graft, made of cobalt-chrome and cellulose promotes tissue regeneration, strength, and ensures blood flow without causing clotting or immune reactions.

The traditional practice of immediately cutting the umbilical cord after birth can pose risks to newborns, causing a dangerous drop in blood flow and oxygen levels. Concord Neonatal offers a solution by allowing babies to receive lifesaving care with the umbilical cord intact until they start breathing on their own. This innovation, aims to prevent birth complications and long-term disabilities, while keeping the baby close to the mother and maximizing the benefits of placental blood until the baby can breathe independently.

Implant Preservation Devices has developed a handheld device to tackle a common problem after joint replacement surgeries prosthetic joint infections (PJI). This device applies heat to implants using induction, effectively targeting and eliminating bacteria that cause these infections. By reducing the risk of recurrent infections, it offers a quick, sterile, and convenient treatment option during surgery, potentially benefiting patients beyond just those undergoing joint replacements.

Scinvivo introduces a solution for bladder cancer diagnosis with its imaging catheter, providing real-time, cross-sectional tissue images. Traditional methods often lead to unnecessary surgeries and missed tumors. By utilizing Optical Coherence Tomography technology, Scinvivo's catheter offers high-resolution imaging, enabling urologists to accurately diagnose bladder conditions. This approach reduces unnecessary surgeries but also enhances diagnostic accuracy, improving patient outcomes.

Our impact
Explore our 2024 Impact report

Invest in a portfolio of companies





